By George Ongkojoyo 
A landmark meta-analysis published on January 16 in The Lancet Obstetrics, Gynaecology & Women’s Health has provided definitive evidence that the use of acetaminophen during pregnancy does not increase the risk of autism, attention-deficit hyperactivity disorder (ADHD), or intellectual disabilities in children. Led by a team of researchers at City St George’s, University of London, this comprehensive review represents the most rigorous evaluation of the medication’s safety to date. The findings offer significant reassurance to millions of expectant mothers and healthcare providers worldwide who rely on acetaminophen—commonly known by the brand name Tylenol in the United States and paracetamol elsewhere—as the primary treatment for pain and fever during pregnancy.
The study arrived at a critical juncture for public health. For several years, conflicting reports and observational studies had suggested a potential link between prenatal exposure to the drug and neurodevelopmental challenges. These concerns reached a peak following highly publicized claims in September 2025, which suggested that paracetamol could potentially interfere with fetal brain development. By synthesizing data from 43 previously published studies, the researchers at City St George’s sought to move beyond statistical correlations and identify whether a causal relationship truly existed.
The Evolution of Medical Guidance on Acetaminophen
Acetaminophen has been a staple of maternal medicine for decades. Due to the known risks associated with non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen—which can cause fetal kidney issues or premature closure of the ductus arteriosus—acetaminophen has long been the "first-line" recommendation for pregnant patients. However, the medical community began to see a rise in observational studies starting in the early 2010s that pointed toward a possible association with ADHD and autism.
These earlier studies often relied on "population-level" data, which tracked large groups of women and their children over time. While these studies found that children whose mothers took acetaminophen were slightly more likely to receive a neurodevelopmental diagnosis, they were frequently criticized for failing to account for "confounding by indication." This scientific term refers to the possibility that the reason a woman took the medication—such as a high fever, a severe infection, or chronic pain—was the actual cause of the developmental outcome, rather than the medication itself.
The September 2025 controversy further complicated the landscape, leading to increased anxiety among expectant parents. The City St George’s team recognized that a more sophisticated analytical approach was required to settle the debate. Their systematic review and meta-analysis were designed to filter out the "noise" of these confounding factors by focusing on the highest-quality evidence available, specifically looking at studies that utilized sibling comparisons.
The Significance of Sibling Comparison Methodology
One of the most robust elements of the new review is its emphasis on sibling comparison studies. Traditional observational research often fails to account for the complex interplay of shared genetics and household environments. For instance, if a mother has a genetic predisposition toward ADHD, her child may inherit that trait regardless of any medication taken during pregnancy. If that same mother also frequently uses acetaminophen for headaches, a simple statistical model might incorrectly blame the drug for the child’s ADHD.
By comparing siblings born to the same mother, researchers can effectively "control" for these variables. In a sibling study, researchers look at one child who was exposed to acetaminophen in the womb and a sibling who was not. Because these children share approximately 50% of their DNA and are typically raised in the same environment by the same parents, any differences in their neurodevelopmental outcomes are much more likely to be linked to the medication exposure.
The scale of the data analyzed in this review was unprecedented. The researchers examined outcomes for:
- 262,852 children assessed for autism.
- 335,255 children evaluated for ADHD.
- 406,681 children assessed for intellectual disability.
Across these massive cohorts, the researchers found that once genetic and environmental factors were accounted for through sibling comparisons, the perceived risk of these conditions vanished. There was no statistically significant evidence that acetaminophen use during pregnancy increased the likelihood of a child developing autism, ADHD, or intellectual disabilities.
Deconstructing the Findings and Research Quality
The research team utilized the Quality In Prognosis Studies (QUIPS) tool to evaluate the risk of bias in each of the 43 studies included in the meta-analysis. This tool examines factors such as how participants were selected, how the medication use was measured, and how the developmental outcomes were diagnosed.
Even when the analysis was restricted to "low-risk" studies—those with the most rigorous designs and least amount of bias—the results remained consistent. Furthermore, the researchers looked at longitudinal data, following children for more than five years after birth. This long-term perspective is vital because neurodevelopmental conditions like ADHD or mild intellectual disabilities are often not diagnosed until a child reaches school age. The lack of a link even in these long-term follow-ups adds a layer of confidence to the findings.
Professor Asma Khalil, Professor of Obstetrics and Maternal Fetal Medicine at City St George’s and the lead author of the study, emphasized that previous "scares" were likely the result of misinterpreting data. "Our findings suggest that previously reported links are likely to be explained by genetic predisposition or other maternal factors such as fever or underlying pain, rather than a direct effect of the paracetamol itself," Khalil stated. She noted that when a mother has a high fever, the body’s inflammatory response and the increased core temperature can pose risks to the developing fetus. In such cases, taking acetaminophen to reduce the fever is actually a protective measure.
Clinical Implications and Professional Reactions
The publication of this review has been met with relief from the broader medical community. Organizations such as the Royal College of Obstetricians and Gynaecologists (RCOG) and various maternal health advocacy groups have historically maintained that acetaminophen is safe, but the lack of a definitive meta-analysis of this scale had left room for public doubt.
Medical experts point out that the risks of not treating symptoms during pregnancy are well-documented. Untreated maternal fever, particularly in the first trimester, is associated with an increased risk of neural tube defects and other congenital anomalies. Chronic, untreated pain can also lead to increased stress levels and high blood pressure in expectant mothers, both of which can negatively impact fetal health.
"The message is clear," Professor Khalil reiterated. "Paracetamol remains a safe option during pregnancy when taken as guided. This is important as paracetamol is the first-line medication we recommend for pregnant women in pain or with a fever, and so they should feel reassured."
While the study provides a robust defense of the medication, the authors did acknowledge certain limitations in the existing body of research. There was insufficient data to determine if the timing of the medication (first, second, or third trimester) made a difference, or if the sex of the baby influenced the outcome. Additionally, the impact of high-frequency, chronic use versus occasional, short-term use could not be fully teased apart due to a lack of detailed reporting in the original sibling studies. These remain areas for future targeted research.
Moving Forward: Restoring Confidence in Prenatal Care
The implications of this study extend beyond the pharmacy counter. In an era of rapid information exchange and social media, "health scares" can lead to widespread "medication hesitancy," even for safe and essential treatments. When pregnant patients avoid necessary medications out of fear, they may turn to unproven alternative therapies or simply suffer through conditions that could harm them or their babies.
This review serves as a course correction for public health messaging. It underscores the importance of high-quality, peer-reviewed evidence in shaping medical guidelines. For clinicians, the data provides a clear talking point for patient consultations: the most comprehensive review of nearly a million child outcomes shows no link between acetaminophen and neurodevelopmental disorders.
As healthcare systems continue to process these findings, the focus will likely shift toward ensuring that patients use the medication as directed—at the lowest effective dose for the shortest possible duration. This "as-needed" approach remains the gold standard for all medications during pregnancy.
The study concluded that the global medical guidance remains sound. Acetaminophen is not only the most practical option for managing pain and fever during pregnancy, but it is also a scientifically defended one. By debunking the link to autism and ADHD, the researchers at City St George’s have provided expectant parents with the peace of mind necessary to prioritize their health and the health of their future children without the burden of unfounded fear.
